

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CONCORD HEALTHCARE GROUP CO., LTD.

美中嘉和醫學技術發展集團股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2453)

CHANGE OF PRESIDENT

The board (the “**Board**”) of directors (“**Director(s)**”) of Concord Healthcare Group Co., Ltd. (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) announces that Ms. FU Xiao has resigned as the president of the Group with effect from January 12, 2026 in accordance with the changes in duties within the Group. Ms. FU Xiao (“**Ms. FU**”) will be an adviser of the Company and continues to be an executive Director of the Group.

Ms. FU has confirmed that she has no disagreement with the Board and the retirement is normal succession planning, and there is no other matter relating to her resignation that needs to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Company would like to express its sincere gratitude to Ms. FU for her valuable contributions to the Company during her tenure of service as the president.

APPOINTMENT OF PRESIDENT

The Board is pleased to announce that Mr. JIANG Wei (“**Mr. JIANG**”) has been appointed as the president with effect from January 12, 2026.

The biographical details of Mr. JIANG are as follows:

Mr. JIANG, aged 45, has been appointed as the president, with effect from January 12, 2026. Mr. JIANG joined the Group in 2020. Since June 2020, he has served as chief executive officer and director of Beijing Healthingkon Technology Co., Ltd., the Group’s core AI business entity. He has also subsequently held the positions of chairman of Shanghai Concord Medical Diagnostic Imaging Limited (上海美中嘉和醫學影像診斷有限公司), director of Guangzhou Concord Cancer Center Co., Ltd. (廣州泰和腫瘤醫院有限公司), director of Shanghai Concord Medical Cancer Hospital Limited* (上海泰和誠腫瘤醫院有限公司), and chief financial officer of Concord Medical Services Holdings Limited. Prior to joining the Group, Mr. JIANG worked at Ernst & Young from July 2003 to June 2007. From July 2007 to May 2020, he was employed by China International Capital Corporation Limited, where he served in various departments including the planning & analysis department, investment banking department, and CICC Capital.

Mr. JIANG obtained a bachelor’s degree of Finance from the School of Economics of Peking University in 2003, and a master’s degree in Business Administration from Guanghua School of Management of Peking University in July 2012.

As the person in charge of the Group's AI business segment, Mr. JIANG has continuously promoted the integration of medical care and AI, driven product innovation, and led the research and development and application of large models for oncology diagnosis and treatment. Going forward, Mr. JIANG will assume the management responsibilities previously held by the former president, with a focus on the Group's core oncology care business. He will deeply integrate the Group's strengths in diagnostic and treatment capabilities, data resources, and AI technology, further build on its expertise in AI-enabled oncology diagnosis and treatment, proactively pursue overseas expansion, and solidify the Group's leading position in the industry.

Mr. JIANG has entered into a service contract with the Company. Mr. JIANG is not appointed as the president for any specific length or proposed length of service but his appointment as the president may be terminated by either party on not less than one month' notice to the other party in writing pursuant to the service contract. Mr. JIANG will receive compensation in accordance with remuneration standard set out in his employment contract with the Group and will not receive additional service fee in his capacity as the president.

As advised by Mr. JIANG, save as disclosed above, Mr. JIANG confirmed that: (i) as at the date of this announcement, he does not hold any other positions with the Company or other members of the Group; (ii) he has not held any directorships in the last three years in any public companies, the securities of which are listed on any securities market in Hong Kong and/or overseas, nor held any other major appointments or professional qualifications; (iii) as at the date of this announcement, he does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (iv) as at the date of this announcement, he has no relationship with any Directors, senior management, substantial shareholders or controlling shareholders of the Company; (v) there is no other information that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on the Stock Exchange (the "Listing Rules"); and (vi) there are no other matters that need to be brought to the attention of the shareholders of the Company.

The Board would like to express its warmest welcome to Mr. JIANG on his appointment.

By order of the Board
Concord Healthcare Group Co., Ltd.
YANG Jianyu
Chairman of the Board and Executive Director

Beijing, the PRC, January 12, 2026

As at the date of this announcement, the Board comprises (i) Dr. YANG Jianyu, Ms. FU Xiao and Mr. CHANG Liang as executive Directors; (ii) Mr. WANG Lei, Mr. SONG Qingbao and Mr. SHI Botao as non-executive Directors; and (iii) Ms. LI Xuemei, Mr. SUN Yansheng and Mr. NG Kwok Yin as independent non-executive Directors.